Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials | Zendy

Bristi Basu | Zendy; J. Vitfell-Pedersen | Zendy; Víctor Moreno | Zendy; M. Puglisi | Zendy; Angelina Tjokrowidjaja | Zendy; Krunal Shah | Zendy; S. Malvankar | Zendy; B. Anghan | Zendy; Johann S. de Bono | Zendy; Stan B. Kaye | Zendy; L Rhoda Molife | Zendy; Udai Banerji | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

Author(s) -

Bristi Basu,

J. Vitfell-Pedersen,

Víctor Moreno,

M. Puglisi,

Angelina Tjokrowidjaja,

Krunal Shah,

S. Malvankar,

B. Anghan,

Johann S. de Bono,

Stan B. Kaye,

L Rhoda Molife,

Udai Banerji

Publication year - 2012

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000341152

Subject(s) - toxicity , medicine , creatinine , renal function , oncology , pharmacology , clinical trial , intensive care medicine

This study aimed to evaluate any correlations between baseline creatinine clearance and the development of grade 3/4 toxicities during treatment within oncology phase I trials of molecularly targeted agents where entry criteria mandate a serum creatinine of ≤ 1.5 × the upper limit of normal.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research